###begin article-title 0
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
###end article-title 0
###begin p 1
Orla Cunningham is currently at Wyeth Research Ireland, Conway Institute, University College Dublin, Dublin 4, Ireland
###end p 1
###begin p 2
###xml 405 412 405 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 472 478 <span type="species:ncbi:10090">murine</span>
The urokinase plasminogen activator (uPA) receptor (uPAR) is a GPI-linked cell surface protein that facilitates focused plasmin proteolytic activity at the cell surface. uPAR has been detected in macrophages infiltrating the central nervous system (CNS) and soluble uPAR has been detected in the cerebrospinal fluid during a number of CNS pathologies. However, its expression by resident microglial cells in vivo remains uncertain. In this work, we aimed to elucidate the murine CNS expression of uPAR and uPA as well as that of tissue plasminogen activator and plasminogen activator inhibitor 1 (PAI-1) during insults generating distinct and well-characterized inflammatory responses; acute intracerebral lipopolysaccharide (LPS), acute kainate-induced neurodegeneration, and chronic neurodegeneration induced by prion disease inoculation. All three insults induced marked expression of uPAR at both mRNA and protein level compared to controls (naive, saline, or control inoculum-injected). uPAR expression was microglial in all cases. Conversely, uPA transcription and activity was only markedly increased during chronic neurodegeneration. Dissociation of uPA and uPAR levels in acute challenges is suggestive of additional proteolysis-independent roles for uPAR. PAI-1 was most highly expressed upon LPS challenge, whereas tissue plasminogen activator mRNA was constitutively present and less responsive to all insults studied. These data are novel and suggest much wider involvement of the uPAR/uPA system in CNS function and pathology than previously supposed. (c) 2009 Wiley-Liss, Inc.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">2002</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">1992</xref>
###xml 698 702 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">1992</xref>
###xml 810 814 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">1991</xref>
###xml 1091 1095 1085 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">2000</xref>
###xml 1096 1100 1090 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">2004</xref>
###xml 1315 1322 1309 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1342 1346 1336 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">1996</xref>
###xml 1460 1464 1454 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">2004</xref>
###xml 1822 1826 1816 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">2000</xref>
###xml 1842 1846 1836 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">2004</xref>
###xml 1865 1869 1859 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">2002</xref>
###xml 1885 1889 1879 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">2000</xref>
###xml 1905 1909 1899 1903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">2001</xref>
###xml 1927 1931 1921 1925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">2004</xref>
###xml 1947 1951 1941 1945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">2002</xref>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 1418 1426 <span type="species:ncbi:9606">patients</span>
###xml 1432 1435 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1694 1697 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The urokinase plasminogen activator (uPA) receptor (uPAR) is a GPI-linked cell-surface protein that is best characterized as a region-specific focus for uPA protease activity at the cell surface. Binding of uPA to uPAR greatly accelerates the cleavage of plasminogen to active plasmin, and the receptor acts to concentrate this activation at discrete membrane locations. This is believed to be a key event in cell adhesion and migration and has been extensively researched in cancer metastases [see (Blasi and Carmeliet,2002) for review]. Monocytes/macrophages are important migratory cells and uPAR has been shown to be expressed by cells of the monocyte lineage (Min et al.,1992; Vassalli et al.,1992) and to be inducible by cytokines, in particular, transforming growth factor beta1 (TGFbeta1) (Lund et al.,1991). Under normal conditions, uPAR expression is negligible and uPAR knockout mice were initially found to be phenotypically normal but further study revealed that, under challenge, they displayed defective recruitment and migration of neutrophils and lymphocytes (Gyetko et al.,2000,2004). Low-level expression of uPAR has been shown in cultured microglial cells, and this expression was increased upon lipopolysaccharide (LPS) stimulation; however, uPAR could not be detected in microglia immediately ex vivo (Washington et al.,1996). Soluble uPAR (suPAR) is elevated in the cerebrospinal fluid (CSF) of patients with HIV dementia (Cinque et al.,2004), and it seems likely that this release of suPAR into the CSF is directly related to increased central nervous system (CNS) inflammation: uPAR has been described in macrophages/microglia within the CNS in traumatic brain injury, HIV dementia, multiple sclerosis, cerebral malaria, Creutzfeldt-Jakob disease (CJD), and Alzheimer's disease (Beschorner et al.,2000; Cinque et al.,2004; Deininger et al.,2002; Fauser et al.,2000; Gveric et al.,2001; Sidenius et al.,2004; Walker et al.,2002). However, clear direct evidence for resident (i.e. noninfiltrating) microglial expression of uPAR is still lacking, and its expression in different CNS insults has not been studied in any systematic way.
###end p 4
###begin p 5
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">1993</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">2005</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">2007</xref>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">2003</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66">1995</xref>
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">1997</xref>
###xml 947 951 947 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">2002</xref>
###xml 968 972 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">2001</xref>
###xml 1079 1083 1079 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">2005</xref>
###xml 1105 1109 1105 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">2005</xref>
###xml 1313 1317 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">1993</xref>
###xml 1429 1433 1429 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">1999</xref>
###xml 1537 1541 1537 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">2005</xref>
###xml 1611 1615 1611 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">1996</xref>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1586 1592 <span type="species:ncbi:9606">humans</span>
It has been recognized for some time that tissue plasminogen activator (tPA) is expressed and is constitutively active in the normal CNS (Sappino et al.,1993), in which it is proposed to have roles in synaptic plasticity, long-term potentiation, and neuronal migration [see Melchor and Strickland (2005) for review]. In addition, tPA activity is decreased in models of Alzheimer's disease, and this is thought to occur through increased expression of PAI-1 (Cacquevel et al.,2007; Melchor et al.,2003). Conversely, tPA activity is increased upon intracerebral injection of kainic acid, and this plasmin activity has a key role in the resulting neurotoxicity (Tsirka et al.,1995,1997). Increased tPA activity in models of prion disease have lead to the suggestion that frustrated attempts by plasmin to proteolytically cleave the deposited form of the prion protein result in bystander damage to neuronal elements during this disease (Ellis et al.,2002; Maissen et al.,2001). However, studies with tPA-/- and plasminogen-/- mice have yielded contradictory results (Salmona et al.,2005; Xanthopoulos et al.,2005). It is clear that tPA has multiple roles in both physiological and pathological situations in the brain. Conversely, uPA has generally been described as being absent from the normal CNS (Sappino et al.,1993). However, uPA is known to be stress responsive and is robustly induced during inflammation (Gabay and Kushner,1999). uPA is expressed in the inflamed CNS in a model of experimental allergic encephalopathy (East et al.,2005) and in cerebral ischemia in rodents and in humans (Rosenberg et al.,1996).
###end p 5
###begin p 6
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">1994</xref>
###xml 196 203 196 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 490 494 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">1992</xref>
###xml 586 591 586 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">1991a</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">b</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">1996</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">2002</xref>
###xml 739 743 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70">2001</xref>
Because it is clear that there is complimentarity and redundancy in the plasmin cascade (Carmeliet et al.,1994), it is important to study, in detail, the expression of constituents of this system in vivo in addition to deleting selected genes. We have studied the expression of uPAR and uPA, as well as tPA and PAI-1, in the CNS in a number of insults that generate distinct and well-characterized inflammatory responses: acute nondegenerative inflammation induced by LPS (Andersson et al.,1992), acute neurodegeneration-associated inflammation induced by kainic acid (Andersson et al.,1991a,b), and chronic neurodegeneration-associated inflammation induced during prion disease (Betmouni et al.,1996; Cunningham et al.,2002; Walsh et al.,2001). Together, these insults generate a range of different innate inflammatory milieu in which uPAR and other components of the plasmin cascade may be expressed in the brain. These different insults induced alterations in the expression/activity of tPA and PAI-1 that were consistent with previous observations, but also revealed novel patterns of uPA and uPAR expression that suggest wider involvement of this system in the CNS than previously supposed.
###end p 6
###begin title 7
EXPERIMENTAL
###end title 7
###begin title 8
Animals and Stereotaxic Surgery
###end title 8
###begin p 9
###xml 177 187 177 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad libitum</italic>
###xml 331 356 330 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Salmonella equine abortus</italic>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 342 348 <span type="species:ncbi:9796">equine</span>
###xml 1039 1044 <span type="species:ncbi:10090">mouse</span>
###xml 1117 1121 <span type="species:ncbi:10090">mice</span>
Female C57BL/6 mice were obtained from Harlan (Bicester, UK), housed in groups of five or six under standard light and temperature regimes, and fed with pelleted food and water ad libitum. For LPS challenges, animals were anesthetized with intraperitoneal avertin, positioned in a stereotaxic frame, and injected with 2.5 mug LPS (Salmonella equine abortus, Sigma, Poole, UK) in 1 muL, via a pulled glass microcapillary tube (coordinates from bregma: anterior-posterior -2.0 mm, lateral -1.6 mm, and depth -1.5 mm). For kainate challenges, 1 nmol of kainic acid (Sigma, Dorset, UK) was injected by exactly the same method as used for LPS. For inoculation with prion disease, animals were anesthetized in the same manner, and 1 muL of a 10% w/v ME7-infected C57BL/6 brain homogenate, made in phosphate-buffered saline (PBS), was injected bilaterally into the dorsal hippocampus (same coordinates) via a 10-muL Hamilton syringe. Control animals were injected with a 10% w/v normal brain homogenate (NBH) in PBS, derived from a naive C57BL/6 mouse. In addition, we made saline challenges and collected tissue from naive mice, both young adult and 8-9 months (age-matched to late stage ME7 and NBH animals). All procedures were carried out in accordance with UK Home Office license.
###end p 9
###begin title 10
Tissue Preparation
###end title 10
###begin p 11
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">1992</xref>
###xml 548 553 548 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">1991a</xref>
###xml 1158 1163 1158 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">2003a</xref>
Animals challenged intracerebrally with LPS were terminally anesthetized at 6, 8, or 72 h post-LPS and examined for evidence of cell infiltration/inflammatory activation, because cytokine expression/microglial activation occurs significantly earlier (6/8 h) than macrophage and neutrophil infiltration (Andersson et al.,1992). Kainate-injected animals were euthanised at 24 h or 72 h post-injection. Neurodegeneration begins synchronously upon kainate challenge but significant macrophage infiltration occurs at 48 h post-kainate (Andersson et al.,1991a) and at 72 h most of the CA1 neurons of the hippocampus show clear morphological signs of nuclear condensation. Animals inoculated with ME7 prion disease were euthanized at 12, 15, 18, 20, and 23 weeks postinoculation for all mRNA studies, with NBH animals taken at 12 and 23 weeks for comparison. For protein expression studies in the ME7 model, this range was narrowed to 13, 18, and 21 weeks postinoculation to reduce animal usage. These times represent points in disease displaying hippocampal synaptic loss, hippocampal neuronal cell soma loss, and terminal disease, respectively (Cunningham et al.,2003a). Tissues were homogenized in PBS with Completetrade mark protease inhibitor cocktail (Roche) and centrifuged at 12,000 rpm for 10 min, and the supernatant was harvested (S1, representing soluble proteins). The pellet was then solubilized by incubation with1% triton-X100 for 1 h at 4degreesC and recentrifuged at 12,000 rpm for 10 min (P1, representing membrane-associated proteins).
###end p 11
###begin p 12
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
All animals used for RNA extraction were terminally anesthetized using sodium pentobarbital, transcardially perfused with heparinized saline, and the brains removed (n = 5 for each animal group). Thick coronal sections (approximately2 mm) were taken at approximately-1.0 to -3.0 mm from Bregma, and the hippocampus and dorsal thalamus were quickly removed, immediately frozen in liquid nitrogen, and stored at -80degreesC.
###end p 12
###begin p 13
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Animal groups for immunohistochemistry were terminally anesthetized and transcardially perfused with heparinized saline and fixed in 10% formalin solution (n = 3 for ME7, LPS, KA). Additional groups were perfused with freshly prepared paraformaldehyde-lysine-periodate fixative (PLP; 2% paraformaldehyde, 0.05% glutaraldehyde, 70 mM lysine, and 10 mM sodium periodate) to preserve the cell-surface markers uPAR and F4/80 (n = 3 for ME7, LPS, KA).
###end p 13
###begin title 14
RNA Extraction
###end title 14
###begin p 15
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DNase1</italic>
###xml 422 423 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 459 460 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 480 481 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 504 505 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Total RNA was extracted from brain samples using Qiagen RNeasy mini columns (Qiagen, Crawley, UK) according to the manufacturer's instructions. Contaminating genomic DNA was degraded during extraction with Qiagen DNase1 enzyme. The typical yield for brain tissue was approximately5 mug per extraction. RNA was stored at -80degreesC until cDNA synthesis and PCR assay. Group sizes for mRNA extraction were as follows: NBH (n = 6), naive, aged and 18-week ME7 (n = 4), 23-week ME7 (n = 5), and all others (n = 3).
###end p 15
###begin title 16
Taqman RT-PCR Assay
###end title 16
###begin p 17
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">1</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">1</xref>
All equipment and reagents were supplied by Applied Biosystems (Warrington, UK) unless otherwise stated. Assays for PAI-1 and tPA were designed using the published sequences for these genes, applied to Primer Express software. Primer and probe sequences for uPA and uPAR were kindly supplied by Prof. Dylan Edwards. The sequences are shown in Table 1. Where possible, probes were designed to cross an intron to ensure that they were cDNA specific. Table 1 lists the sequences for primers and probes for each assay. All primer pairs were checked for specificity by standard RT-PCR using Promega PCR reagents (Southampton, UK) followed by gel electrophoresis. Each primer pair produced a discrete band of the expected amplicon size (not shown).
###end p 17
###begin p 18
Sequences of Primers and Probes Used in Quantitative TaqMan Analyses
###end p 18
###begin p 19
###xml 321 325 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">2005</xref>
###xml 910 911 908 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 911 912 909 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
For Taqman PCR, cDNA was generated from total RNA using Taqman Gold RT reagents. Two hundred nanograms of total RNA were reverse transcribed in a 10-muL reaction volume. One microliter of the RT reaction (equivalent to 20-ng RNA) was subsequently used for the PCR and performed as previously described (Cunningham et al.,2005). A standard curve was constructed from total RNA isolated from mouse brain tissue after intracerebral challenge with 2.5 mug LPS, which is known to upregulate all target transcripts of interest in this study. This standard curve was constructed using a higher concentration of RNA in the reverse transcriptase reaction than for samples for analysis to ensure that transcription in all animal groups would fall within the range of the standard curve constructed. Serial 1 in five dilutions of the cDNA synthesized from brains of LPS-injected mice were made and a curve plotted of the Ct value (the cycle number at which the transcribed gene crosses the threshold of detection) versus the log of the concentration (assigned an arbitrary value since the absolute concentration of cytokine transcripts is not known). Thus, the standard curve generates arbitrary values for concentration. These data were then normalized for GAPDH concentration in each sample.
###end p 19
###begin title 20
Western Immunoblotting
###end title 20
###begin p 21
###xml 825 828 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1349 1355 1347 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Fig. 1</xref>
###xml 1435 1439 1433 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">2009</xref>
###xml 423 428 <span type="species:ncbi:10090">mouse</span>
###xml 612 622 <span type="species:ncbi:7227">Drosophila</span>
###xml 809 816 <span type="species:ncbi:9986">Rabbits</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
###xml 898 904 <span type="species:ncbi:9986">rabbit</span>
###xml 1106 1112 <span type="species:ncbi:9986">rabbit</span>
###xml 1125 1130 <span type="species:ncbi:10090">mouse</span>
###xml 1324 1330 <span type="species:ncbi:10090">murine</span>
###xml 1417 1421 <span type="species:ncbi:10090">mice</span>
Pellet-enriched fractions were prepared as described for P1 (see tissue preparation) from LPS, kainate, and ME7 animals and analyzed for uPAR protein expression by western blot. Briefly, 25 mug of each lysate was loaded and run under reducing conditions on a 10% SDS-PAGE gel. Samples were transferred to PVDF, blocked in 5% nonfat milk in PBS-T (PBS and 0.2% Tween-20) for 2 h, and probed overnight with a polyclonal anti-mouse uPAR antibody (anti-smuPAR) at 1 mug/mL. The antibodies against uPAR, both polyclonal and monoclonal, were produced using recombinant smuPAR expressed in Schneider S2 cells using the Drosophila Expression System Kit (Invitrogen) as antigen. The protein was purified from the conditioned media of stably transfected S2 cells using Ni-NTA beads (Qiagen) followed by gel filtration. Rabbits and uPAR-/- mice were immunized with recombinant smuPAR, and the IgG fraction of rabbit serum and hybridoma conditioned media were subsequently affinity purified on a column containing immobilized smuPAR (Sidenius, unpublished work). Detection was achieved with a 1:5,000 dilution of anti-rabbit-HRP or anti-mouse-HRP (GE Healthcare) and development with ECL reagent (PIERCE). The appropriate uPAR detection and specificity of this antibody were verified by transfection of Chinese Hamster Ovary cells with murine uPAR (Supp. Info. Fig. 1) and by staining of kidney tissue from wild type and uPAR-/- mice (Tjwa et al.,2009).
###end p 21
###begin p 22
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 412 420 412 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 473 474 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 593 594 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Quantitative PCR analysis of gene expression changes in uPAR, uPA, tPA, and PAI-1. Total RNA was isolated from hippocampus at various time points (LPS: 24 h, KA: 48 h, Saline, 24 h, and ME7 as described on x-axis). Synthesized cDNA was analyzed using TAQMAN PCR using specific primers and probes designed from published sequences for these genes. Statistical significance was determined by ANOVA with Bonferroni post hoc tests and P values are denoted by * (P < 0.001), **(P < 0.01), and ***(P < 0.05). Group sizes for mRNA extraction were as follows: NBH (n = 6), nave, aged and 18-week ME7 (n = 4), 23-week ME7 (n = 5), and all others (n = 3).
###end p 22
###begin title 23
Plasminogen Activation Assay
###end title 23
###begin p 24
###xml 1051 1055 1046 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">2007</xref>
Samples were analyzed for plasminogen activation activity in an indirect enzymatic assay in a 96-well format using the chromogenic plasmin substrate Chromozym PL (Roche) with output at 410 nm. Reactions were carried out in assay buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl) containing a final concentration of 0.2 muM plasminogen (Sigma), 0.2 mM chromozym PL, and 50-mug protein extract. Where a distinction between tPA and uPA activity was desired, selective inhibitors of each of the plasminogen activators were used. For tPA inhibition, a commerical tPA inhibitor, tPA Stop (American Diagnostica, Stamford, CT), was included in the reaction mix at a final concentration of 1.5 muM. uPA was inhibited using amiloride (Sigma) at a final concentration of 0.2 mM. Although these inhibitors are not entirely specific, they do show good selectivity at the concentrations used: 0.2 mM amiloride significantly inhibits uPA while having a minimal effect on tPA activity while the Ki of tPA STOP is 0.035 muM for tPA and 3.4 muM for uPA (Harvey and Chintala,2007). Samples were allowed to run overnight at room temperature, and data were collected using a DYNEX MRX plate reader using Revelation software (Worthing, UK).
###end p 24
###begin title 25
Gel zymography for tPA and uPA Activity
###end title 25
###begin p 26
###xml 140 141 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 159 160 159 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 645 646 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Enzyme activities for tPA and uPA were assessed using gel zymography. A substrate solution of 8% w/v Marvel dry milk in PBS, containing CaCl2 (0.9 mM) and MgCl2 (1.0 mM), was prepared. A 10% SDS-PAGE gel was prepared with 400 muL of 8% milk solution per 20 mL of resolving gel. In addition, 133 muL of plasminogen (1.5 mg/mL; Sigma P-7397) was added to the resolving gel. Solubilized pellets and supernatants (15-mug protein per lane) were added to loading buffer without mercaptoethanol and were not boiled before loading on the gel. Gels were run at 25 mA per minigel. The gels were rinsed in 2.5% Triton X-100 and then incubated in 10 mM CaCl2, 50 mM Tris (pH 7.6) for 6 h at 37degreesC. After this time, the gel was rinsed again and stained in Coomassie blue for 1 h before destaining until areas of proteolysis became apparent as clear areas in the intense blue staining of the remaining casein protein throughout the gel.
###end p 26
###begin title 27
Immunohistochemistry for uPAR and F4/80
###end title 27
###begin p 28
###xml 566 567 554 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 568 569 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 679 684 <span type="species:ncbi:10090">Mouse</span>
###xml 688 693 <span type="species:ncbi:10090">Mouse</span>
###xml 695 698 <span type="species:ncbi:10090">MOM</span>
###xml 746 749 <span type="species:ncbi:10090">MOM</span>
###xml 782 785 <span type="species:ncbi:10090">MOM</span>
###xml 1040 1045 <span type="species:ncbi:9796">horse</span>
###xml 1051 1056 <span type="species:ncbi:10090">mouse</span>
###xml 1082 1085 <span type="species:ncbi:10090">MOM</span>
###xml 1307 1313 <span type="species:ncbi:9986">rabbit</span>
###xml 1475 1481 <span type="species:ncbi:9986">rabbit</span>
###xml 1487 1490 <span type="species:ncbi:10116">rat</span>
Immunohistochemistry was carried out for uPAR and F4/80. All biotinylated secondary antibodies were supplied by Vector laboratories (Peterborough, UK) and all staining was visualised using the ABC method using peroxidase as enzyme, 0.015% v/v hydrogen peroxide as substrate and diaminobenzidine as chromagen. Frozen paraformaldehyde-lysine-periodate-fixed brain sections were cut on a cryostat and stored at -20degreesC. On removal from the freezer sections were dried at 37degreesC for 30 min. Endogenous peroxidase was quenched using methanol containing 1 ml 30% H2O2 for 20 min. Sections were washed with PBS-Tween (0.1%) and blocked using both Vector Avidin-Biotin block and Mouse-On-Mouse (MOM) blocking reagents. After 1 h of blocking with MOM blocking diluent and 5 min with MOM working solution, the primary monoclonal antibody BR4.8 (Sidenius, unpublished) was applied at 2 mug/ml and left to incubate in a humidified chamber for 2 h. This antibody was then washed off and sections were washed overnight in PBS-Tween. Biotinylated horse anti-mouse antibody was prepared in MOM diluent and left at room temperature for 30 min. ABC incubation and DAB staining were then performed as normal. Sections for F4/80 staining were oven dried and washed as before and then blocked for 30 min with normal 10% rabbit serum before incubation with the F4/80 antibody (Serotec, Oxford, UK) for 1 h at room temperature. The sections were then washed and incubated with biotinylated rabbit anti-rat antibody for 45 min and continued through ABC incubation and DAB/peroxidase reaction as before.
###end p 28
###begin title 29
Statistical Analysis
###end title 29
###begin p 30
###xml 273 281 273 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
Gene expression data were analyzed by comparing all "acute" groups (naive, saline, LPS, and KA) or all "chronic" groups (NBH, 12 weeks, 15 weeks, 18 weeks, 20 weeks, 23 weeks, and age-matched naive) by one-way ANOVA followed by selected pair-wise comparisons by Bonferroni post hoc tests. Significance was accepted at the 95% confidence interval.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
Transcriptional Regulation of PA Components during CNS Inflammation
###end title 32
###begin p 33
###xml 54 58 <span type="species:ncbi:10090">mice</span>
After RNA isolation from brain homogenates of treated mice, cDNA was synthesized and examined for transcription of uPAR, uPA, tPA, and PAI-1.
###end p 33
###begin p 34
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">1</xref>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 634 635 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Transcription of uPAR was markedly increased for all challenges compared to their relevant control groups (Fig. 1a). LPS induced a 41-fold increase with respect to naive animals and a 15-fold increase with respect to saline-injected animals (P < 0.001). KA induced a 50-fold increase with respect to naive and an 18-fold increase with respect to saline-injected animals (P < 0.001). Injection of saline alone increased uPAR expression with respect to naive animals. This was not statistically significant when all acute groups were compared, but when compared in the absence of LPS and KA groups, this difference is readily apparent (P < 0.001).
###end p 34
###begin p 35
###xml 280 288 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 608 616 596 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 616 617 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
To investigate expression in chronic inflammation, we compared ME7 prion-diseased animals with NBH controls. NBH animals at 23 weeks postinoculation showed low-uPAR levels, similar to both aged-matched and young naive animals (not significantly different by ANOVA with Bonferroni post hoc test). In contrast, ME7 animals showed a clear and time-dependent increase in expression of uPAR with disease progression, reaching approximately15-fold elevation compared to NBH animals by 20 weeks postinoculation. This increase is apparent by 12 weeks and statistically significant by 15 weeks (ANOVA with Bonferroni post hocP < 0.001).
###end p 35
###begin p 36
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">1</xref>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 508 516 496 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 516 517 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
The mRNA for the protease uPA shows only variable and limited induction by LPS at 24 h or kainate at 72 h (Fig. 1b), and these increases are not statistically significant at these time points (no main effect by one-way ANOVA, no post hoc tests performed). In ME7 animals, by contrast, uPA transcription was markedly induced, by approximately17-fold by 20 weeks postinoculation. This increase is once again time-dependent, with induction already apparent and statistically significant at 12 weeks (Bonferroni post hocP < 0.01). There were no significant differences between saline-injected, NBH-injected, or young or older naive mice.
###end p 36
###begin p 37
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">1</xref>
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 370 371 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 432 433 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
tPA is constitutively expressed in the brain and mRNA expression levels accordingly appear high at baseline and are less inducible (Fig. 1c). LPS challenge induced a moderate increase in expression with respect to naive (P < 0.001) and to saline-treated animals (P < 0.01), but saline also induced a modest, though nonsignificant increase with respect to naive animals (P > 0.05). tPA expression was induced in KA-injected animals (P < 0.01 versus naive animals), but the induction was highly variable, and this increase did not reach statistical significance with respect to saline-treated animals. There is also a trend toward a time-dependent increase in tPA expression during prion disease progression, but even at peak expression, levels are only increased approximately twofold with respect to NBH controls and this does not reach statistical significance.
###end p 37
###begin p 38
###xml 23 24 23 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">1</xref>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PAI-1 expression (Fig. 1d) was markedly induced by LPS compared to levels of expression in saline-treated animals (P < 0.001). PAI-1 was also induced in KA-injected animals but only to a modest and highly variable degree (nonsignificant, P > 0.05). PAI-1 was clearly induced with the progression of prion disease. This increase did not become statistically significant until 18 weeks (P < 0.05) and by 23 weeks was elevated approximately sixfold.
###end p 38
###begin title 39
uPAR Protein Expression During CNS Inflammation
###end title 39
###begin p 40
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 670 675 670 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">2003b</xref>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">1990</xref>
###xml 880 881 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 991 995 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">1990</xref>
###xml 1024 1030 1012 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Fig. 2</xref>
###xml 1606 1607 1591 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 1822 1823 1807 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 514 519 <span type="species:ncbi:10090">mouse</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
###xml 681 687 <span type="species:ncbi:9606">humans</span>
###xml 1184 1189 <span type="species:ncbi:10090">mouse</span>
###xml 1215 1219 <span type="species:ncbi:9925">goat</span>
###xml 1225 1231 <span type="species:ncbi:9986">rabbit</span>
###xml 1378 1384 <span type="species:ncbi:9986">rabbit</span>
Hippocampal homogenates were prepared at 8 h and 3 days after intracerebral injection with LPS and from animals 8 h after saline injection. Further homogenates were prepared from kainate-injected hippocampi 24 and 72 h after challenge or 24 h after saline injection. Homogenates from NBH animals (21 weeks) and ME7 animals (13, 18, and 21 weeks) were also prepared. These times are justified in the Experimental section. Homogenates were analyzed by PAGE and Western blotting for uPAR protein levels using an anti-mouse polyclonal antibody, and the results are summarized in Figure 2a. Because of its marked glycosylation, previously observed in mice (Cunningham et al.,2003b) and humans (Roldan et al.,1990), uPAR runs as a smear at between 45 and 60 kDa. LPS induced a marked expression of uPAR protein at 8 h postinjection and a dramatic increase by 3 days posttreatment (Fig. 2a). A further band at approximately35 kDa may represent the unglycosylated form of the protein (Roldan et al.,1990). Further data (Supp. Info. Fig. 2) show that the pattern of uPAR expression/glycosylation is not yet altered 2 h post-LPS, but is altered at 6 h and markedly so at 24 h. Immunoblots with mouse anti-beta-actin and with goat anti-rabbit IgG on the same membrane verified that all lanes show approximately equal loading and that the observed bands are a consequence of binding of the rabbit antimurine uPAR antibody. uPAR was expressed at very low levels in saline-treated animals. Kainate-injected animals also showed clear expression of uPAR at 24 h postinjection with respect to saline-treated controls (Fig. 2b). This expression appeared to decrease by 3 days. ME7 animals showed a time-dependent increase in uPAR expression, with marked expression by 13 weeks and continued increases at 18 and 21 weeks, respectively (Fig. 2c). NBH controls showed no evidence of uPAR expression in the brain.
###end p 40
###begin p 41
###xml 262 263 260 261 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 308 309 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 332 333 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 382 383 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 406 407 404 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
###xml 456 457 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
Western blot analysis of uPAR expression in hippocampal homogenates. Membrane fraction samples (25 mug protein) were separated by SDS-PAGE, transferred to PVDF, immunoblotted with a polyclonal antisoluble mouse uPAR antibody at 1 mug/mL and developed with ECL. (a) LPS (8 or 72 h) or saline treatment (8 h) (n = 3 for all groups). (b) Kainate (24 or 72 h) and saline groups (24 h) (n = 3 for all groups). (c) ME7 (13, 18, and 21 weeks) and NBH (21 weeks) (n = 4 for each group: one representative gel shown.).
###end p 41
###begin title 42
Confirmation of both tPA and uPA Expression and Activity in the CNS
###end title 42
###begin p 43
Because mRNA expression analysis indicated that both uPA and tPA activities may be present in some of the innate inflammatory responses under study, we examined this possibility further using both gel zymography and soluble assays in the presence of selective inhibitors. In these experiments, brain homogenates from progressive stages of prion disease were analyzed.
###end p 43
###begin p 44
###xml 200 201 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">3</xref>
###xml 547 548 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">3</xref>
The gel zymography method separates tPA and uPA activities on the basis of size, with tPA running at a molecular weight of approximately67 kDa and uPA, in its pro form, at approximately50 kDa. Figure 3a shows that uPA protein increases in a time-dependent manner during the course of prion disease, consistent with the mRNA data. Under the same conditions, tPA protein expression is constitutively high with less marked increases observed with disease progression. In this case, the majority of tPA is associated with the soluble fraction. Figure 3b illustrates that both uPA and tPA activities are present in membrane fractions of the ME7 brain, with comparable fractions of total plasminogen activation being inhibited by selective tPA and uPA inhibitors [tPA stop (1.5 mum) and amiloride (0.2 mM) respectively]. These inhibitors may also affect the activity of plasminogen activators even when receptor-bound, which may be significant given the ability of the plasminogen activators to act as soluble of receptor-bound forms.
###end p 44
###begin p 45
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 359 360 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 482 483 470 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 600 601 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Zymographic and 96-well soluble assay of plasmin activity in ME7 animals. (a) Plasmin activity was assessed in both soluble and membrane fractions by in-gel zymography. The activity of both tPA and uPA are visible on the gel at MWs of approximately67 and 50 kDa, respectively (pro forms). Samples are in duplicate and one representative gel of two performed (n = 4) is shown. Images have been captured by digital camera and reversed to increase the clarity of the banding pattern. (b) Plasmin activity was assessed by 96 well assay using ChromazymPL as substrate. Data represent the mean +/- SEM for n = 4 in each experimental group. Selective inhibition of plasmin activity at 18 weeks postinoculation with ME7 prion disease using selective inhibitors of tPA (tPA stop, 1.5 mum) and uPA (amiloride, 0.2 mM) revealed the presence of both activities in this membrane fraction.
###end p 45
###begin title 46
Plasminogen Activation During Distinct CNS Pathologies
###end title 46
###begin p 47
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">4</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">4</xref>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">4</xref>
Gel zymography analysis showed the presence of both uPA and tPA in the brain and associated increases during the progression of prion disease. However, zymography cannot assess the activities of these enzymes in solution, because inhibitors such as PAI-1 may remain bound on the nonreducing gel. To assess the effects of the three distinct CNS insults on total plasminogen activation, activity was measured in total brain homogenates as described earlier (those used for zymography). Both soluble and membrane-associated homogenate fractions were analyzed in each case. An increase in total plasminogen activation with progression of prion disease is apparent in both soluble and membrane fractions (Fig. 4a,b, respectively). This increase is more apparent, and clearly time-dependent, in PA associated with the membrane fraction. Similar total PA increases are evident after kainate challenge (Fig. 4c). However, total PA activity decreases after LPS challenge (Fig. 4d). Only soluble fractions are shown for kainate and LPS challenges as the trend is similar for membrane-associated fractions in both cases.
###end p 47
###begin p 48
###xml 155 156 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 216 217 216 217 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 278 279 278 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
###xml 348 349 348 349 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</bold>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Total plasmin activity in soluble and/or membrane fractions of homogenates of hippocampal tissue from animals injected with NBH, ME7, LPS, KA, or saline. (a) Soluble fractions of NBH and ME7 (13, 18, and 21 weeks). (b) Membrane fractions of NBH and ME7 (13, 18, and 21 weeks). (c) Soluble fractions of KA (24 and 72 h) and saline-injected (24 h). (d) Soluble fractions of LPS (8 and 72 h) and saline-injected animals (8 h). Data represent the mean for n = 4 in each experimental group. Error bars have been omitted for clarity, owing to the frequency of sampling.
###end p 48
###begin title 49
Cellular Localization of uPAR in the CNS
###end title 49
###begin p 50
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">1999</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 899 903 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">2000</xref>
###xml 1071 1072 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 1208 1209 1208 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 1290 1291 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 1483 1487 1483 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">1996</xref>
###xml 1652 1653 1652 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 1749 1750 1749 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
Immunolabeling revealed that uPAR is expressed in cells with typical, classical microglial morphologies (Streit et al.,1999) in all three conditions and also in infiltrating macrophages after LPS challenge. The staining levels are very low in saline-injected (Fig. 5a) and NBH-injected control animals (Fig. 5c), but there was nonetheless, labeling of the highly ramified processes of microglial cells in their normal quiescent state (5 o,p). The staining was clearly increased in animals 8-h post-LPS challenge, and this staining revealed microglial cells maintaining a ramified morphology (Fig. 5b). Animals examined 3 days after LPS challenge showed evidence of diffuse extracellular uPAR staining, apparently throughout the parenchyma, consistent with cleavage of GPI-linked uPAR to increase suPAR levels (Fig. 5j). Cleavage and shedding of uPAR is well documented in monocytes (Sidenius et al.,2000). In the same manner, uPAR was upregulated 3 days post-KA challenge on microglial cells with shortened processes in the vicinity of the dying neurons of the CA1 (Fig. 5e,i,s,t). Furthermore, the contralateral side to KA injection also showed hyper-ramified microglial staining with uPAR expression (Fig. 5d,q,r). ME7 animals also showed clear evidence of microglial uPAR staining (Fig. 5f) with microglia showing upregulation of uPAR throughout the hippocampus and dorsal thalamus, as has been shown previously for other microglial markers in this disease model (Betmouni et al.,1996). Similar to LPS and KA challenges, ME7 animals also showed evidence of diffuse uPAR staining in the parenchyma that was not associated with particular cells (Fig. 5h) and was increased relative to the very low-parenchymal labeling in NBH-treated animals (Fig. 5c,g).
###end p 50
###begin p 51
###xml 96 99 96 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a&#8211;j</bold>
###xml 191 194 191 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k&#8211;n</bold>
###xml 1205 1208 1205 1208 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o&#8211;t</bold>
Cellular localization of uPAR expression. PLP-fixed brain sections were immunostained for uPAR (a-j) to identify the cellular source of uPAR in the brain after various insults and for F4/80 (k-n) to confirm morphology and location of macrophages/microglia following these insults. Low-level staining of highly ramified microglial processes can be observed in control animals; (a) saline (8 h) and (c) NBH (18 weeks). Increased expression is evident in (b) LPS (8 h) tissue and (d) contralateral to KA challenge, though the morphology remains quite ramified. Marked expression of uPAR is evident in amoeboid microglia ipsilateral to KA challenge (e) and in condensed microglia in ME7-treated animals (f). In addition to cellular staining, uPAR appears to be released into the parenchyma after ME7 (h), KA (i), and LPS (j) challenges. The site of injection is indicated by *. F4/80 staining reveals constitutive labelling of ramified microglial cells in NBH controls (k). The levels of F4/80 and cell morphology are altered in ME7 (l), KA (m), and LPS 3 days (n). uPAR and F4/80 are also shown at 100x magnification to illustrate the similar morphologies of the cells positively labeled for these antigens (o-t). Both markers display the ramified (saline: o, p), hyper-ramified (kainate contralateral: q, r) and activated/amoeboid (kainate ipsilateral: s, t). Scale bars = 70 mum (a-f), 1 mm (g-j), 50 mum (k-n), and 10 mum (o-t).
###end p 51
###begin p 52
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 997 998 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">5</xref>
###xml 1320 1324 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">1992</xref>
We also stained for F4/80 after the various challenges used in this study to confirm the morphology and location of macrophages/microglia following these insults. F4/80 immunostaining revealed constitutive labeling of ramified microglial cells in NBH and saline-injected animals (Fig. 5k,p), and this morphology was shared by uPAR-positive cells (Fig. 5o). The levels of expression of the F4/80 antigen and the morphology of macrophages/microglia are altered in LPS, KA, and ME7-injected animals (Fig. 5n,m,l, respectively). This is most obvious ipsilateral to KA challenge, after which the microglial processes become shorter and condensed, and these cells invade the degenerating CA1 neuronal layer (Fig. 5m). This classical activated/amoeboid morphology is clearly shown by both uPAR and F4/80 (Fig. 5s,t). Significantly, the hyper-ramified morphology typical of "alert" microglia was also observed on the contralateral side to the kainate challenge and also is displayed by both markers (Fig. 5q,r). Thus, F4/80-staining parallels the cellular staining observed with the anti-uPAR antibody in its morphology and localization after the different challenges. Significantly, uPAR expression is present in resident microglial cells before any infiltration of cells from the bloodstream has taken place (Andersson et al.,1992).
###end p 52
###begin title 53
DISCUSSION
###end title 53
###begin p 54
###xml 389 396 389 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 78 84 <span type="species:ncbi:10090">murine</span>
###xml 547 553 <span type="species:ncbi:10090">murine</span>
###xml 654 660 <span type="species:ncbi:10090">murine</span>
We have shown here that uPAR is expressed by resident microglial cells of the murine brain and that it is significantly upregulated in the brain in response to a number of challenges that provoke an innate immune response. At peak expression, there is considerable shedding of this GPI-linked protein from the cell surface into the brain parenchyma. This is the first clear demonstration, in vivo, that resident microglia as well as infiltrating macrophages expresses this protein. In addition, we have shown expression and activity of uPA in the murine brain, particularly during the progression of chronic neurodegeneration caused by the ME7 strain of murine prion disease. There are interesting dissociations between the inductions of uPA and uPAR among the various challenges studied here. Both LPS and kainate-induced neurodegeneration led to very marked inductions of uPAR with minimal effect on uPA expression, whereas chronic neurodegeneration induces uPA and uPAR transcriptional increases of similar magnitude (14-20-fold) perhaps indicating divergent roles of protease activity in these models.
###end p 54
###begin title 55
uPAR and uPA Expression in the Brain
###end title 55
###begin p 56
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">1992</xref>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">1992</xref>
###xml 246 250 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">2000</xref>
###xml 263 267 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b75">2004</xref>
###xml 435 439 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">2000</xref>
###xml 440 444 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">2004</xref>
###xml 515 523 505 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 642 649 632 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 686 690 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">1996</xref>
###xml 904 908 894 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">2000</xref>
###xml 923 927 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">2004</xref>
###xml 946 950 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">2002</xref>
###xml 966 970 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">2000</xref>
###xml 986 990 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">2001</xref>
###xml 1008 1012 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">2004</xref>
###xml 1028 1032 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">2002</xref>
###xml 1334 1338 1324 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">2002</xref>
###xml 1659 1663 1649 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">2006</xref>
###xml 780 783 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Monocytes/macrophages are known to express uPAR (Min et al.,1992; Vassalli et al.,1992), and levels of expression are reported to be elevated during endotoxemia and by various cytokines including IL-1beta, TNF-alpha, and TGFbeta1 (Dekkers et al.,2000; Yue et al.,2004). The expression of uPAR and its site-directed focusing of uPA activity play a central role in cell migration and infiltration to sites of inflammation (Gyetko et al.,2000,2004). Low-level expression of uPAR has been described in microglial cells in vitro, and this expression was increased upon LPS stimulation; however, uPAR could not be detected in microglia immediately ex vivo by these authors (Washington et al.,1996). There have been reports of brain macrophage/microglial cell surface uPAR expression in HIV dementia, multiple sclerosis, cerebral malaria, traumatic brain injury, CJD, and Alzheimer's disease (Beschorner et al.,2000; Cinque etal.,2004; Deininger et al.,2002; Fauser et al.,2000; Gveric et al.,2001; Sidenius et al.,2004; Walker et al.,2002). Some of these studies show either double staining with macrophage markers or morphology suggestive of microglial cells. However, most of these studies describe conditions in which macrophages have recently infiltrated the brain. Even in a chronic disease, such as Alzheimer's disease (Walker et al.,2002), in which uPAR positive staining is colocalized with CD68-positive macrophages, it is not clear whether these are resident or infiltrating cells, because bone marrow-derived infiltrating macrophages have been reported to be selectively targeted to amyloid plaques in animal models of Alzheimer's disease (Simard et al.,2006).
###end p 56
###begin p 57
###xml 929 933 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">1993</xref>
###xml 949 953 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">2001</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">1999</xref>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
In this study, we demonstrate that uPAR is expressed in resident microglial cells in the normal brain and in both acute and chronic inflammation. Immunohistochemistry reveals that uPAR is expressed at very low levels in naive and saline-treated mice but is significantly upregulated by LPS many hours before cell infiltration occurs, demonstrating that resident microglial cells upregulate this cell surface marker upon stimulation. In light of its role in cell migration, the expression of uPAR by infiltrating macrophages in the brain was readily rationalized. Although the need for local extracellular protease activity is not so obvious for resident cells, recent data demonstrate that microglia continually explore their local microenvironment, and these cells are well known to respond rapidly to transient neural activity suppression by stimulation with potassium chloride (cortical spreading depression: (Gehrmann et al.,1993; Jander et al.,2001) and to show activation in undamaged regions, distal to ischemic lesions (Schroeter et al.,1999). In this regard, it is interesting that in our studies even saline challenges produce measurable increases in uPAR gene expression when compared with naive animals and that uPAR is robustly expressed in hyper-ramified microglia contralateral to kainate challenges, indicating that even minor disturbances to the brain parenchyma provoke transcriptional, translational, and perhaps structural changes in microglial cells. The interaction of uPA with uPAR may thus contribute to morphological changes and migration toward relatively proximal stimuli.
###end p 57
###begin p 58
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">2002</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">2008</xref>
###xml 737 745 737 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 950 954 950 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">2007</xref>
###xml 1305 1309 1305 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1991</xref>
It is also possible that uPAR has roles in brain inflammation that are entirely dissociated from the focusing of uPA activity. We show here that uPAR is highly expressed after both kainate and LPS challenges, but that uPA is not significantly upregulated under the same conditions. There is now a large body of evidence to support multiple proteolysis-independent roles for uPAR in cell adhesion, migration, proliferation, and differentiation outside the CNS [reviewed in Blasi and Carmeliet (2002)]. Recent experiments suggest that uPAR has a uPA-independent role in ischemic damage (Nagai et al.,2008). A second, key-binding partner of uPAR is the extracellular matrix protein vitronectin (VN). Overexpression of uPAR in HEK-293 cells in vitro and subsequent uPAR-VN interaction was shown to induce profound changes in cell morphology, including cell spreading and rearrangement of the actin cytoskeleton and focal adhesion contacts (Madsen et al.,2007). This cell-matrix interaction could be postulated to mediate the morphological changes that are observed upon activation of resident microglia, leading to the less-ramified, more-condensed morphology after inflammatory challenges. In addition, VN has been shown to be present in diffuse and dense core plaques in Alzheimer's disease (Akiyama et al.,1991), and its interaction with uPAR may also influence microglial activation at the plaque periphery.
###end p 58
###begin p 59
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">2001</xref>
###xml 626 627 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">2007</xref>
###xml 824 828 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">2008</xref>
We also observed variation in uPAR glycosylation with different challenges. Levels of uPAR protein expression are most robustly induced after acute LPS challenge, and it is also this condition that leads to the highest level of uPAR glycosylation (Fig. 2a). In contrast, uPAR glycosylation is not as marked during the development of prion disease (Fig. 2c). Time-dependent changes in uPAR glycosylation levels have previously been observed during monocyte activation, and this has been shown to be correlated with protein-protein interactions important in mediating cell adhesion (Mahoney et al.,2001). Similar alterations in N-glycosylation patterns have recently been reported in a number of inflammatory conditions including sepsis, acute pancreatitis, and systemic lupus erythematosus (Gornik et al.,2007; Hashii et al.,2008), and the significance of different glycosylation patterns in the current data merits further study.
###end p 59
###begin p 60
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">2004</xref>
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">2002</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">2005</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b73">2002</xref>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">2002</xref>
###xml 1361 1365 1361 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">2008</xref>
###xml 1453 1461 1453 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 299 302 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The high levels of uPAR expression observed in the current study, during CNS inflammation induced by three distinct challenges (chronic neurodegeneration, acute neurotoxicity, and acute non-neurotoxic LPS), can perhaps explain the frequently reported elevations of suPAR in the CSF of patients with HIV dementia and other CNS conditions (Cinque et al.,2004; Garcia-Monco et al.,2002; Sporer et al.,2005; Winkler et al.,2002). Conversely, neither stroke nor demyelinating diseases such as MS or Guillian-Barre syndrome resulted in elevated CSF suPAR despite comprising significant inflammatory components (Garcia-Monco et al.,2002). It seems likely that release of suPAR into the CSF is directly related to increased CNS inflammation as we observed considerable diffuse staining, that was not cell-associated, in the parenchyma in addition to microglial labeling. This would suggest that uPAR is unlikely to have specific diagnostic utility for any particular CNS condition but is likely to be a reliable indicator of current CNS inflammation. It would appear that many types of inflammation result in shedding of suPAR from the microglial cell surface in the brain; however, other factors, currently unknown, may determine uPAR's escape to the CSF. Likewise, findings that cell-surface levels of uPAR are controlled by endocytosis and recycling (Cortese et al.,2008) should be replicated in microglia, although this would be more easily addressed using in vitro approaches.
###end p 60
###begin title 61
uPA or tPA?
###end title 61
###begin p 62
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">1993</xref>
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66">1995</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">1997</xref>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">2001</xref>
###xml 571 575 571 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">2001</xref>
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">1996</xref>
###xml 742 746 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">2008</xref>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">1995</xref>
###xml 1250 1254 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">1995</xref>
###xml 1271 1275 1257 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">1993</xref>
###xml 1276 1280 1262 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">1995</xref>
###xml 1299 1303 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">1993</xref>
###xml 1315 1319 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">1992</xref>
###xml 1334 1338 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">1996</xref>
###xml 1420 1424 1406 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">2003</xref>
###xml 1522 1526 1505 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">2002</xref>
###xml 1545 1549 1528 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">2000</xref>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10116">rats</span>
###xml 528 534 <span type="species:ncbi:9606">humans</span>
###xml 673 676 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
Tissue plasminogen activator (tPA) is constitutively active in the rodent brain (Sappino et al.,1993) and contributes to the neurotoxicity of kainic acid in rodent studies (Tsirka et al.,1995,1997) and, in this regard, our finding that tPA rather than uPA is upregulated after kainate challenge is consistent with the consensus view of kainate-induced microglial expression of neurotoxic tPA. Nonetheless, there is clear evidence that uPA rather than tPA is the key plasminogen activator in cerebral ischemia in mice, rats, and humans (Cinelli et al.,2001; Hosomi et al.,2001; Rosenberg et al.,1996), and it has recently been described as coexpressed with uPA in brains of HIV patients with opportunistic cerebral infections (Nebuloni et al.,2008). So, what governs whether either or both plasminogen activators are switched on during inflammation? It is well described that uPA is robustly upregulated by macrophage CSF-1 (Stacey et al.,1995), and we have found evidence for increased transcription of CSF-1 in the ME7 prion disease model (unpublished observations). In addition, both tPA and uPA have been described to be differentially regulated in multiple cell types by IL-1alpha/beta, TNFalpha, TGFbeta1, and prostaglandin E2 (Allan and Martin,1995; Falcone et al.,1993,1995; Gerritsen et al.,1993; So et al.,1992; Zhang et al.,1996). All these mediators are produced by intracerebral LPS challenges (Boche et al.,2003), but TGFbeta1 and PGE2 would appear to dominate in ME7-induced prion disease (Cunningham et al.,2002; Minghetti et al.,2000). Clearly, the regulation of tPA and uPA in the brain requires considerably more investigation.
###end p 62
###begin p 63
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">2000</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">2001</xref>
###xml 310 318 310 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 345 347 345 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">2002</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">2004</xref>
###xml 496 498 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">2005</xref>
###xml 773 777 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">2005</xref>
###xml 888 892 888 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">2005</xref>
###xml 1119 1123 1119 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">2005</xref>
###xml 1352 1356 1352 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">2005</xref>
###xml 1724 1726 1724 1726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 983 988 <span type="species:ncbi:10090">mouse</span>
There have been a number of studies published describing a role for plasminogen activation in prion disease, but these studies have been focussed on tPA. Initial studies demonstrated a direct interaction between plasminogen and disease-associated PrP (Fischer et al.,2000; Maissen et al.,2001), and subsequent in vitro studies suggested that PrPSc specifically activated tPA without effect on uPA (Ellis et al.,2002; Epple et al.,2004). Despite this, there is evidence that tPA cannot degrade PrPSc (Xanthopoulos et al.,2005). The role of plasminogen and tPA in prion disease is further clouded by divergent results when plasminogen deficient animals (plg-/-) were inoculated with prion disease: one study reports a very slight protection of plg-/- animals (Salmona et al.,2005), while the other reports that plasminogen deficiency prompts earlier symptoms and death (Xanthopoulos et al.,2005). These studies are both compromised by the adverse phenotype of the plasminogen knockout mouse, which shows poor health, retarded growth, and shortly after inoculation, becomes runted, listless, and cachectic (Salmona et al.,2005). With such an adverse phenotype attributing symptoms and/or death to prion disease rather than gene deficiency become problematic, perhaps reflected in the very large variability observed in the studies of Xanthopoulos et al. (2005). Our current studies are suggestive of increases in both tPA and uPA, as shown by partial inhibition by both amiloride and tPA, and by the presence of both activities in zymographic analysis. In addition, the increased transcription of uPA is very prominent in this disease model given its very low constitutive expression. Whether uPA synthesis is a response to PrPSc deposition, has a role in microglial migration/phagocytosis in concert with uPAR, or affects some other aspect of neuroprotection/neurodegeneration remains unclear but certainly merits further study.
###end p 63
###begin title 64
The Influence of PAI-1
###end title 64
###begin p 65
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b67">2000</xref>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">2003</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">3</xref>
###xml 846 853 846 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1023 1027 1013 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">1995</xref>
###xml 1136 1140 1126 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">2003</xref>
###xml 1280 1284 1270 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">1996</xref>
###xml 1302 1306 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">2008</xref>
###xml 1570 1572 1560 1562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1761 1768 1751 1758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1110 1115 <span type="species:ncbi:10090">mouse</span>
In models of Alzheimer's disease, both tPA and uPA have been reported to show increased expression (Tucker et al.,2000). However, tPA activity has been shown by in situ zymography to be decreased in AD models, and its activity is proposed to be controlled by the substantial increases in PAI-1 (Melchor et al.,2003). We also observed PAI-1 elevation in prion disease but despite its probable presence in the soluble assay, we still observe considerable increases in plasmin activation (Fig. 3a). This raises an interesting point about PAI-1 expression. In the current studies, we have observed clear increases in plasmin activity in both ME7- and KA-treated animals, but decreased activity in LPS-treated animals. LPS produced the most marked transcriptional increase in PAI-1, suggesting that PAI-1 expression may be the ultimate determinant of in vivo plasmin activity. IL-1beta, TNF-alpha, and TGFbeta1 have all been shown to induce PAI-1 robustly and to bring about decreased plasminogen activation (Faber-Elman et al.,1995), and it is well known that LPS i.c. challenges induce all these cytokines in the mouse brain (Boche et al.,2003). Because tPA contributes to neuronal death during excitotoxicity and uPA to ischemic and cytokine-induced neurotoxicity (Rosenberg et al.,1996; Thornton et al.,2008) suppression of these activities during LPS challenges may be one major reason why this robust inflammatory stimulus is not overtly neurotoxic. Likewise, the dominance of tPA/uPA over their inhibitors in prion disease may have a beneficial effect, in clearing PrPSc, or a deleterious effect in causing bystander proteolytic damage. Furthermore, the balance of PAI-1 and tPA/uPA from a neuroanatomical point of view may be key in this regard. Preliminary in situ zymography data suggest that both plasminogen activator activities are present in the hippocampus (not shown), but considerably more work is required to clarify this. Nonetheless, specific targeting of uPA and/or PAI-1 may produce interesting effects in the ME7 model of prion disease, irrespective of previous manipulations of tPA.
###end p 65
###begin title 66
CONCLUSION
###end title 66
###begin p 67
###xml 76 84 <span type="species:ncbi:9606">patients</span>
A number of clinical studies have shown that uPAR is elevated in the CSF of patients with a variety of CNS degenerative and/or inflammatory diseases. These clinical studies have not been matched by similar basic research efforts to understand the involvement of uPAR in these inflammatory situations. This study suggests that uPAR may be involved in a very wide variety of inflammatory and pathological situations in the brain and systematic studies of its role and that of uPA may contribute significantly to our understanding of many of these conditions and to a greater understanding of microglial biology.
###end p 67
###begin p 68
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
The authors thank the Company of Biologists for a travel grant awarded to OC and Prof Dylan Edwards for primer and probe sequences for uPA and uPAR. We also thank Marc Tjwa for the use of control images from Plau-/- mice.
###end p 68
###begin title 69
REFERENCES
###end title 69
###begin article-title 70
Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue
###end article-title 70
###begin article-title 71
###xml 156 159 <span type="species:ncbi:10116">rat</span>
Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts
###end article-title 71
###begin article-title 72
The CNS acute inflammatory response to excitotoxic neuronal cell death
###end article-title 72
###begin article-title 73
The kinetics and morphological characteristics of the macrophage-microglial response to kainic acid-induced neuronal degeneration
###end article-title 73
###begin article-title 74
The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues
###end article-title 74
###begin article-title 75
###xml 182 188 <span type="species:ncbi:9606">humans</span>
Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI, FCI in humans
###end article-title 75
###begin article-title 76
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Evidence for an early inflammatory response in the central nervous system of mice with scrapie
###end article-title 76
###begin article-title 77
uPAR: A versatile signalling orchestrator
###end article-title 77
###begin article-title 78
Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo
###end article-title 78
###begin article-title 79
Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms
###end article-title 79
###begin article-title 80
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Physiological consequences of loss of plasminogen activator gene function in mice
###end article-title 80
###begin article-title 81
Neuroserpin, a neuroprotective factor in focal ischemic stroke
###end article-title 81
###begin article-title 82
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations
###end article-title 82
###begin article-title 83
Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR
###end article-title 83
###begin article-title 84
###xml 76 82 <span type="species:ncbi:10090">murine</span>
Synaptic changes characterize early behavioural changes in the ME7 model of murine prion disease
###end article-title 84
###begin article-title 85
Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions
###end article-title 85
###begin article-title 86
###xml 59 65 <span type="species:ncbi:10090">murine</span>
Transforming growth factor beta1, the dominant cytokine in murine prion disease: Influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix
###end article-title 86
###begin article-title 87
Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease
###end article-title 87
###begin article-title 88
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor
###end article-title 88
###begin article-title 89
###xml 73 78 <span type="species:ncbi:9606">human</span>
Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia
###end article-title 89
###begin article-title 90
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis
###end article-title 90
###begin article-title 91
Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner
###end article-title 91
###begin article-title 92
Both lysine-clusters of the NH2-terminal prion-protein fragment PrP23-110 are essential for t-PA mediated plasminogen activation
###end article-title 92
###begin article-title 93
Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways
###end article-title 93
###begin article-title 94
Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor
###end article-title 94
###begin article-title 95
THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor
###end article-title 95
###begin article-title 96
###xml 94 99 <span type="species:ncbi:9606">human</span>
Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria
###end article-title 96
###begin article-title 97
Binding of disease-associated prion protein to plasminogen
###end article-title 97
###begin article-title 98
Acute-phase proteins and other systemic responses to inflammation
###end article-title 98
###begin article-title 99
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases
###end article-title 99
###begin article-title 100
###xml 27 30 <span type="species:ncbi:10116">rat</span>
Microglial reaction in the rat cerebral cortex induced by cortical spreading depression
###end article-title 100
###begin article-title 101
###xml 23 28 <span type="species:ncbi:9606">human</span>
Cytokine activation of human macro- and microvessel-derived endothelial cells
###end article-title 101
###begin article-title 102
Changes of serum glycans during sepsis and acute pancreatitis
###end article-title 102
###begin article-title 103
Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage
###end article-title 103
###begin article-title 104
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro
###end article-title 104
###begin article-title 105
###xml 96 118 96 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pseudomonas aeruginosa</italic>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 96 118 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection
###end article-title 105
###begin article-title 106
Inhibition of plasminogen activators attenuates the death of differentiated retinal ganglion cells and stabilizes their neurite network in vitro
###end article-title 106
###begin article-title 107
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Alteration of N-glycosylation in the kidney in a mouse model of systemic lupus erythematosus: Relative quantification of N-glycans using an isotope-tagging method
###end article-title 107
###begin article-title 108
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion
###end article-title 108
###begin article-title 109
###xml 86 89 <span type="species:ncbi:10116">rat</span>
Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain
###end article-title 109
###begin article-title 110
###xml 121 126 <span type="species:ncbi:9606">human</span>
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells
###end article-title 110
###begin article-title 111
uPAR-induced cell adhesion and migration: Vitronectin provides the key
###end article-title 111
###begin article-title 112
###xml 72 77 <span type="species:ncbi:9606">human</span>
Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes
###end article-title 112
###begin article-title 113
Plasminogen binds to disease-associated prion protein of multiple species
###end article-title 113
###begin article-title 114
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration
###end article-title 114
###begin article-title 115
Tissue plasminogen activator in central nervous system physiology and pathology
###end article-title 115
###begin article-title 116
###xml 57 62 <span type="species:ncbi:9606">human</span>
cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator
###end article-title 116
###begin article-title 117
###xml 68 73 <span type="species:ncbi:9606">human</span>
Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies
###end article-title 117
###begin article-title 118
###xml 80 86 <span type="species:ncbi:10090">murine</span>
Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke
###end article-title 118
###begin article-title 119
###xml 107 135 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases
###end article-title 119
###begin article-title 120
###xml 43 48 <span type="species:ncbi:9606">human</span>
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
###end article-title 120
###begin article-title 121
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat
###end article-title 121
###begin article-title 122
Role of plasminogen in propagation of scrapie
###end article-title 122
###begin article-title 123
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Extracellular proteolysis in the adult murine brain
###end article-title 123
###begin article-title 124
###xml 90 93 <span type="species:ncbi:10116">rat</span>
Heterogeneity of the microglial response in photochemically induced focal ischemia of the rat cerebral cortex
###end article-title 124
###begin article-title 125
###xml 70 75 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease
###end article-title 125
###begin article-title 126
Shedding and cleavage of the urokinase receptor (uPAR): Identification and characterisation of uPAR fragments in vitro and in vivo
###end article-title 126
###begin article-title 127
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease
###end article-title 127
###begin article-title 128
###xml 123 128 <span type="species:ncbi:9606">human</span>
Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells
###end article-title 128
###begin article-title 129
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients
###end article-title 129
###begin article-title 130
Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor
###end article-title 130
###begin article-title 131
Reactive microgliosis
###end article-title 131
###begin article-title 132
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity
###end article-title 132
###begin article-title 133
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells
###end article-title 133
###begin article-title 134
Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin
###end article-title 134
###begin article-title 135
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
###end article-title 135
###begin article-title 136
The plasmin system is induced by and degrades amyloid-beta aggregates
###end article-title 136
###begin article-title 137
Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: A localized and regulated proteolytic system
###end article-title 137
###begin article-title 138
###xml 101 106 <span type="species:ncbi:9606">human</span>
Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains
###end article-title 138
###begin article-title 139
###xml 45 51 <span type="species:ncbi:10090">murine</span>
Absence of detectable IL-1beta production in murine prion disease: A model of chronic neurodegeneration
###end article-title 139
###begin article-title 140
###xml 89 94 <span type="species:ncbi:9606">human</span>
Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia
###end article-title 140
###begin article-title 141
The systemic and local acute phase response following acute brain injury
###end article-title 141
###begin article-title 142
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Role of the urokinase plasminogen activator system in patients with bacterial meningitis
###end article-title 142
###begin article-title 143
Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies
###end article-title 143
###begin article-title 144
Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor
###end article-title 144
###begin article-title 145
###xml 39 42 <span type="species:ncbi:10116">rat</span>
Regulation of plasminogen activator in rat endometrial stromal cells: The role of prostaglandin E2
###end article-title 145
###begin title 146
Supplemental material
###end title 146

